Researcher
Eric Van Cutsem
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
1 - 10 of 12
- SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancersFrom1 Jan 2022 → TodayFunding: Foundations, funds and other with scientific goal
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- Genetic biomarkers for anti-angiogenic therapies - a translational approach.From1 Jan 2011 → 31 Dec 2013Funding: Private funding of national origin - undefined
- The role of the forkhead transcription factor FOXP1 in cancer.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Technical research platform & heavy equipment HiSeq200 (including CBOT computing system and warranty).From1 Sep 2010 → 31 Aug 2013Funding: Other federal scientific institutions
- Can response to Epidermal Growth Factor Receptor antibodies in patients with metastatic Colorectal Cancer be predicted? Advanced bio-informatics tools, integrating gene mutation, microarray and proteomics data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
- Imaging for early response prediction to EGF-receptor blocking monoclonal antibodies in combination therapy for colorectal cancer.From1 Jan 2009 → 31 Dec 2012Funding: IWT - TBM (Applied Biomedical Research)
- Can response to epidermal growth factor receptor antibodies in metastatic colorectal cancer be predicted? Advanced bio-informatics tools integrating gene mutation and microarray data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: Private funding of national origin - undefined
- A phase I dose-escalation study to determine the maximum tolerated dose of radiotherapy, in combination with concomitant 5-FU chemptherapy, in patients with locally advanced rectal cancer with a positive circumferential resection margin (cCRM).From1 Jan 2009 → 31 Dec 2010Funding: Private funding of national origin - undefined
Publications
551 - 560 of 726
- Early tumor shrinkage and long-term outcome in metastatic colorectal cancer: assessment of predictive utility across treatment arms in the crystal and opus studies(2011)
Authors: Hubert Piessevaux, Eric Van Cutsem, Carsten Bokemeyer, Michael Schlichting, Steffen Heeger, Sabine Tejpar
Pages: v14 - v15 - ASSESSMENT OF TUMOR GENOTYPES IN METASTATIC COLORECTAL CANCER (MCRC): MUTATIONS BEYOND KRAS CODONS 12 AND 13 AS PREDICTIVE BIOMARKERS OF RESPONSE TO PANITUMUMAB (PMAB) IN A RANDOMIZED, PHASE 3 STUDY(2011)
Authors: Marc Peeters, Kelly S Oliner, Salvatore Siena, Eric Van Cutsem, Jing Huang, Yves Humblet, Jean-Luc Van Laethem, Thierry Andre, Jeffery Wiezorek, Scott D Patterson
Pages: v15 - v15 - Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status(2011)
Authors: Eric Van Cutsem, Sabine Tejpar
Pages: 2011 - 2019 - Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 129676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803(2011)
Authors: Eric Van Cutsem
Pages: 990 - 996 - Self-Rated Pain Assessment by Patients With HER2-Positive Advanced Gastric/GEJ Cancer Treated With 5-FU/Capecitabinc and Cisplatin With or Without Trastuzumab: Exploratory QOL Analysis From the Phase III ToGA Study(2011)
Authors: Yoon-Koo Kang, Lin Shen, Mikhail Lichinitser, Brad L Stanford, Manuel Philco, Yung-Jue Bang, Eric Van Cutsem, Harald A Weber, Nedal Al-Sakaff, Anthony R Pritchard, et al.
Pages: S204 - S204 - European initiatives in colorectal cancer screening(2011)
Authors: Eric Van Cutsem
Pages: 201 - 203 - Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation(2011)
Authors: Albert Wolthuis, Freddy Penninckx, Karin Haustermans, Nadine Ectors, Eric Van Cutsem
Pages: 684 - 690 - Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study(2011)
Authors: Eric Van Cutsem
Pages: 256 - 262 - Selectieve interne radiotherapie met yttrium-90-microsferen voor primaire levertumoren en levermetastasen(2011)
Authors: Christophe Deroose, Sam Heye, Chris Verslype, Eric Van Cutsem, Hans Wildiers, Hans Prenen, Robert Paridaens, Karin Haustermans
Pages: 115 - 125 - Quality assurance in colonoscopy for colorectal cancer diagnosis(2011)
Authors: Eric Van Cutsem
Pages: 10 - 15